Medical Advocates
Cytomegalovirus Infection/Disease
 
Main Page
 
New/Noteworthy 
 Pregnant Women/Neonates 
 Pediatric CMV 
General Reports  
 Risk Factors  
Epidemiology/Incidence
Resistance 
Diagnosis/Monitoring
Prevention 


 		 Systemic Infection
Transplant CMV  
Management
Drugs 
 Economic Data
Retinal Disease




 
OI Main Page Disease Main Page Main New/Noteworthy Home Page 
Last Update:  August 14, 2010
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
August  2010
 
General Reports/Reviews
       

      Journal Papers, Abstracts, and Commentaries   

 
Cytomegalovirus-induced infectious mononucleosis-like syndrome in a rheumatoid arthritis
patient treated with methotrexate and infliximab.
Shimojima Y, Ishii W, Matsuda M,  et al.
Intern Med. 2010;49(10):937-40.
Abstract
 
A spread deficient cytomegalovirus for assessment of first target cells in vaccination.
Mohr CA, Arapovic J, Mühlbach H, et al
 J Virol. 2010 May 12
 Abstract
 
Modulation of host innate and adaptive immune defenses by cytomegalovirus:
timing is everything.
Loewendorf A, Benedict CA. 
J Intern Med. 2010 May;267(5):483-501.
 

Co-infection with cytomegalovirus and Epstein-Barr virus in mononucleosis: case report and
review of literature.
Olson D, Huntington MK.
S D Med. 2009 Sep;62(9):349, 351-3.
 Abstract

Cellular normalization of viral DNA loads on whole blood improves the clinical management of cytomegalovirus
or Epstein Barr virus infections in the setting of pre-emptive therapy.
Bressollette-Bodin C, Coste-Burel M, Besse B, et al 
J Med Virol. 2009 Jan;81(1):90-8
 Abstract
 
Presumed fuchs heterochromic iridocyclitis and Posner-Schlossman syndrome: comparison of
cytomegalovirus-positive and negative eyes.
Chee SP, Jap A. 
Am J Ophthalmol. 2008 Dec;146(6):883-9.e1
 Abstract
 
Cytomegalovirus and human immunosenescence.
Pawelec G, Derhovanessian E, Larbi A,  et al
Rev Med Virol. 2008 Nov 26
 Abstract
 
Infusion of Cytomegalovirus Specific Cytotoxic T Lymphocytes From a Sero-Negative Donor Can
Facilitate Resolution of Infection and Immune Reconstitution.
Horn B, Bao L, Dunham K, et al 
Pediatr Infect Dis J. 2008 Nov 19
 Abstract
 
Cytomegalovirus reactivation in critically ill immunocompetent patients.
Limaye AP, Kirby KA, Rubenfeld GD, et al  
JAMA. 2008 Jul 23;300(4):413-22
 Abstract
 
Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease.
Britt W.
Curr Top Microbiol Immunol   2008;325:417-70
 Abstract
 
Human Cytomegalovirus Secretome Contains Factors That Induce Angiogenesis and Wound Healing.
 Dumortier J, Streblow DN, Moses AV, et al
J Virol. 2008 Apr 30.
 Abstract
 
Role of the cytomegalovirus major immediate early enhancer in acute infection and
reactivation from latency.
Stinski MF, Isomura H. 
Med Microbiol Immunol. 2007 Dec 19
Abstract
 
The history of cytomegalovirus and its diseases.
Ho M.
Med Microbiol Immunol. 2007 Dec 18
Abstract
 
Cytomegalovirus infection: a driving force in human T cell immunosenescence.
Koch S, Larbi A, Ozcelik D, et al 
Ann N Y Acad Sci. 2007 Nov;1114:23-35
 Abstract
 
High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection
with seroconversion.
Ziemann M, Krueger S, Maier AB, et al  
Transfusion. 2007 Nov;47(11):1972-83.
 Abstract
 
The immunological burden of human cytomegalovirus infection.
Khan N.
Arch Immunol Ther Exp (Warsz). 2007 Oct 1
 Abstract
 
Active CMV disease does not always correlate with viral load detection.
Ruell J, Barnes C, Mutton K, et al  
Bone Marrow Transplant. 2007 Apr 30;
 Abstract
 
Healthy Aging and Latent Infection with CMV Lead to Distinct Changes in CD8(+) and
CD4(+) T-Cell Subsets in the Elderly.
Weinberger B, Lazuardi L, Weiskirchner I, et al  
Hum Immunol. 2007 Feb;68(2):86-9
 Abstract
 
The interplay between host and viral factors in shaping the outcome of cytomegalovirus
infection.
Scalzo AA, Corbett AJ, Rawlinson WD, et al 
Immunol Cell Biol. 2006 Dec 5;
 Abstract
 
Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART).
Steininger C, Puchhammer-Stockl E, Popow-Kraupp T.
J Clin Virol. 2006 May 1;
Abstract

Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection:
correlation with protection from CMV disease.
Stone SF, Price P, French MA.
J Antimicrob Chemother. 2006 Apr;57(4):585-8.
Abstract
 
CMV as a cofactor enhancing progression of AIDS.
Griffiths PD.
J Clin Virol. 2006 Jan 12;
 Abstract
 
Cytomegalovirus mononucleosis as a cause of prolonged fever and prominent weight loss
 in immunocompetent adults.
Rodriguez-Bano J, Muniain MA, Borobio MV, et al 
Clin Microbiol Infect. 2004 May;10(5):468-70.
 Abstract

Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood
products.
Nichols WG, Price TH, Gooley T, et al
Blood 2003 Jan 16
 Abstract 

Cytomegalovirus infection in immunocompetent patients.
Wreghitt TG, Teare EL, Sule O, et al  .
Clin Infect Dis. 2003 Dec 15; 37(12): 1603-6.
 Abstract 

Unusual manifestations of primary cytomegalovirus infection in patients without HIV
infection and without organ transplants.
Crowley B, Dempsey J, Olujohungbe A, et al. 
J Med Virol 2002 Oct;68(2):237-40
 Abstract 

 
 
Risk Factors
       
          Journal Papers, Abstracts, and Commentaries 
 
  Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted
unrelated bone marrow: analysis of infectious complications in patients treated with T cell
depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
van Burik JA, Carter SL, Freifeld AG, et al.  
Biol Blood Marrow Transplant. 2007 Dec;13(12):1487-98
 Abstract 
Prevention
Transplant CMV Prophylaxis      
          Journal Papers, Abstracts, and Commentaries   
 
 
Cytomegalovirus vaccines and methods of production (WO20009049138): the
emerging recognition of the importance of virus neutralization at the epithelial/endothelial
interface.
Schleiss MR.
Expert Opin Ther Pat. 2010 Apr;20(4):597-602.
 Abstract

Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant.
Pass RF.
J Clin Virol. 2009 Jul 30.
 Abstract

Late-onset CMV disease following CMV prophylaxis.
Donnelly C, Kennedy F, Keane C, et al
 Ir J Med Sci. 2009 Apr 2
 Abstract
 
Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects.
Wloch MK, Smith LR, Boutsaboualoy S, et al
J Infect Dis. 2008 Apr 29.
 Abstract
 
  New prophylactic treatment strategy for cytomegalovirus disease.
Lake KD. 
Am J Health Syst Pharm. 2003 Dec 1; 60(23 Suppl 8): S13-6
 Abstract
 
  Formulary considerations for drugs used to prevent cytomegalovirus disease.
Pescovitz MD.  
Am J Health Syst Pharm. 2003 Dec 1; 60(23
 Abstract
Resistance
 
      Journal Papers, Abstracts, and Commentaries
 
  Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and
clinical impact.
Baldanti F, Gerna G. 
J Antimicrob Chemother. 2003 Jul 29
Abstract 
 
  Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with
cytomegalovirus retinitis.
Jabs DA, Martin BK, Forman MS, et al 
Am J Ophthalmol 2003 Jan;135(1):26-34
 Abstract 
Economic Studies
             

         Journal Papers, Abstracts, and Commentaries

  Cost advantages of oral drug therapy for managing cytomegalovirus disease.
Somerville KT.
Am J Health Syst Pharm. 2003 Dec 1;60(23 Suppl 8):S9-12.
 Abstract

OI Main Page Disease Main Page Main New/Noteworthy Home Page 

CMV Infection Main Page